BTIG raised the firm’s price target on Astrana Health to $60 from $50 and keeps a Buy rating on the shares ahead of its Q2 results. The company looks well positioned to benefit from good acute care industry volumes, better bio-pharma R&D spending and capital markets activity, some pressure on Managed Care MLRs, and good labor force markets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Announces Major Acquisitions and Earnout Agreement
- Astrana Health and Elation Health partner in infrastructure solution
- Astrana Health and Anthem Blue Cross partner in California
- Astrana Health upgraded to Buy from Hold at Truist
- Astrana Health price target raised to $48 from $45 at Stifel
Questions or Comments about the article? Write to editor@tipranks.com